Physician profile
Mark William Rolfe
NPI 1255426417
$2,860.84
in general payments reported to CMS, 2019-2025
22 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,407 · 2020: $93.59 · 2021: $100 · 2022: $338 · 2023: $326 · 2024: $367 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,184.52 | 2019-2020 | |
| Abbott Laboratories | $324.85 | 2021-2023 | Cardiomems |
| Paragonix Technologies, INC. | $217.16 | 2024 | Sherpapak, Liverguard, Pancreaspak |
| Abiomed | $197.23 | 2022-2023 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.82 | 2023-2025 | Ofev, Jardiance |
| Actelion Pharmaceuticals US, INC. | $116.73 | 2024 | Opsumit, Uptravi |
| Insmed, INC. | $107.92 | 2019 | |
| Melinta Therapeutics, LLC | $97.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $83.28 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $53.84 | 2023 | Assure Wcd |
| Paratek Pharmaceuticals, INC. | $45.13 | 2025 | Nuzyra |
| Janssen Pharmaceuticals, INC | $36.80 | 2023 | Xarelto |
| Veloxis Pharmaceuticals, INC. | $35.15 | 2019 | |
| Abbvie INC. | $33.40 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.94 | 2025 | Livtencity |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $22.08 | 2019 | |
| Kci USA, INC. | $20.96 | 2019 | |
| Intercept Pharmaceuticals, INC. | $20.16 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.65 | 2022-2023 | Lifevest |
| Kiniksa Pharmaceuticals, LTD. | $14.59 | 2023 | Arcalyst |
| Medtronic, INC. | $13.60 | 2023 | Mc3 Nautilus(Tm) Ecmo Oxygenator |
| Tetraphase Pharmaceuticals, INC. | $12.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Rolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.